Enanta Pharmaceuticals, Inc. (ENTA) Stock Price & Analysis
Enanta Pharmaceuticals, Inc. (ENTA) is trading at USD 8.14, down 6.35% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ENTA last closed at USD 8.14; today's session has ranged USD 8.11–8.75 on volume of 628,251 shares. Market capitalization is —, with a 52-week range of USD 8.11–17.15 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ENTA.md
Latest Earnings Results (ENTA)
Enanta Pharmaceuticals, Inc. (ENTA) reported Q4 2026 results on Nov 16, 2026, 4:10:15 PM ET: GAAP EPS -$0.81 vs. estimate -$0.77 (miss), revenue $12.87M vs. estimate $15.72M (miss). Guidance: The company expects its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029. Source: SEC 8-K filing. Nexqual published it 17 min 49 s after release. Read the SEC filing. Full report with estimates: nexqual.com/earnings/2026-11-16/ENTA.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q4 2026 | -$0.81 (GAAP diluted) | $12.9M | Nov 16, 2026, 4:10:15 PM ET · on Nexqual +17 min 49 s | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (ENTA)
- Last four reported quarters (through Jun 30, 2026): revenue $65.3M, net income -$63.2M (-96.9% margin), free cash flow -$36.9M (SEC filings).
- Total return with dividends: 1Y -34.1% vs S&P 500 +11.9%; 5Y -89.2% vs S&P 500 +66.7%.
- Next earnings: 2027-02-08 (date not yet confirmed by the company), EPS estimate USD -0.33, revenue estimate $14.3M.
- Dividend: ENTA paid no cash dividend in the last five years.
- Short interest: 7.63% of float (as of 2026-10-30), 7.0 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENTA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M | $65.3M |
| Operating income | -$110M | -$124M | -$137M | -$122M | -$85.3M | -$58.7M |
| Net income | -$79.0M | -$122M | -$134M | -$116M | -$81.9M | -$63.2M |
| EPS (diluted) | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 | — |
| Free cash flow | -$70.7M | -$86.9M | -$112M | -$96.7M | -$32.2M | -$36.9M |
| Operating margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% | -90.0% |
| Net margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% | -96.9% |
| Revenue growth | -20.7% | -11.2% | -8.1% | -14.6% | -3.4% | — |
| Cash + short-term investments | $244M | $249M | $370M | $248M | $189M | — |
Fiscal years end Sep. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ENTA)
Analysts (ENTA)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | HC Wainwright & Co. | Reiterated | Buy | $20 |
Total return (dividends reinvested) (ENTA)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | -34.1% | -89.2% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -34.2% | -35.9% |
| Volatility (annualized) | 53.5% | 66.3% |
| Max drawdown | -51.7% (Dec 2025→Nov 2026) | -94.9% (Nov 2021→Apr 2025) |
Dividends (ENTA)
ENTA paid no cash dividend in the last five years.
Short interest (ENTA)
1,856,510 shares sold short, 7.63% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,552,994 shares (-27.3%). Days to cover: 7.0 (short shares ÷ average daily volume).
ENTA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.81 | −$0.77 | Miss −5.2% | -20.9% |
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.67 | −$0.53 | Miss −26.4% | -1.8% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.45 | −$0.57 | Beat +21.1% | -5.3% |
| Feb 9, 2026 | Quarter ended Dec 31, 2025 | −$0.42 | −$0.80 | Beat +47.5% | +4.6% |
| Nov 17, 2025 | — | — | — | — | +2.5% |
| Aug 11, 2025 | — | — | — | — | -0.6% |
| May 12, 2025 | — | — | — | — | -0.8% |
| Feb 10, 2025 | — | — | — | — | +14.1% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ENTA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 18, 2026 | 10-K | Annual report · period ended Sep 30, 2026 |
| Nov 16, 2026 | Schedule 13G | ADAR1 Capital Management, LLC, Daniel Schneeberger: 6.0% of shares, passive 5%+ holder |
| Nov 16, 2026 | 8-K | Quarterly results |
| Nov 16, 2026 | Schedule 13G/A | Farallon Capital Management, L.L.C., Dapice Joshua J.: 3.3% of shares, passive 5%+ holder (amended) |
| Oct 29, 2026 | 8-K | Other material event “As previously disclosed, Enanta Pharmaceuticals, Inc. (the "Company") filed a patent infringement action in the Unified Patent Court (the "UPC") of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the " 265 Patent") in connection with Pfizer's manufacture, use, and sale of Paxlovid (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for…” |
| Oct 28, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “On October 28, 2026, Enanta Pharmaceuticals, Inc. (the "Company") and Jay R. Luly, Ph.D., age 70, announced Dr. Luly's intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. The Company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027. The Board of Directors (the "Board") of the Company has initiated a comprehensive search for Dr. Luly's successor, considering…” |
| Oct 27, 2026 | Schedule 13G | BlackRock Portfolio Management LLC: 5.4% of shares, passive 5%+ holder |
| Aug 14, 2026 | Schedule 13G/A | Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.0% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.3% of shares, passive 5%+ holder (amended) |
| Aug 12, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 10, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ENTA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | “We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.” |
| Competitor | Merck (MRK) | “AbbVie's MAVYRET/MAVIRET regimen currently competes in various geographic markets and HCV patient populations with Gilead's Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a fixed-dose combination of sofosbuvir, velpatasvir and voxilaprevir approved by the FDA for certain adults previously treated with direct-acting antivirals), Harvoni® (a fixed-dose combination of sofosbuvir and ledip…” |
Quoted from the company's 10-K filed Nov 18, 2026.
ENTA company outlook (results filed Nov 16, 2026)
- “Topline Data Expected in 1Q 2027 • Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes;”
- “Topline Phase 2b Data Expected in 2027 • Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027 • Investigational New Drug (IND) Application Filing for EDP-903, an Oral, Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027 • Selected MRGPRX2 Development Candidate EPS-5336 for the Treatment of Mast Cell-Driven Diseases Including Migraine;”
- “Kieffer, Ph.D. to Chief Operating Officer • Cash and Marketable Securities Totaling $194.5 Million at September 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 WATERTOWN, Mass., November 16, 2026 – Enanta Pharmaceuticals, Inc.”
- “In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027.”
Quoted word-for-word from the SEC 8-K results press release.
ENTA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.33 | $-0.41 | +$0.08 | $14.3M | 1 |
| Next quarter (ends Mar 2027) | $-0.42 | $-0.47 | +$0.05 | $12.5M | 1 |
| Current fiscal year (ends Sep 2027) | $-3.19 | $-2.37 | −$0.82 | $64.1M | 2 |
| Next fiscal year (ends Sep 2028) | $-2.27 | $-1.91 | −$0.36 | $86.4M | 4 |
ENTA options: expected move
Options price a move of about ±57.5% (±$5.17) by Apr 16, 2027, which includes earnings on Feb 8, 2027. Over the last 8 reports the stock moved ±6.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 235.1% | ±27.3% |
| Jan 15, 2027 | 58 | 121.6% | ±18.4% |
| Apr 16, 2027 | 149 | 96.7% | ±57.5% |
30-day implied volatility 87% vs 81.8% realized over the last 30 trading days. Put/call ratio (volume) 34. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 8.14 |
|---|---|
| Change | ▼ 6.35% (down) |
| Previous Close | USD 8.14 |
| Open | USD 8.14 |
| Day Range | USD 8.11 – 8.75 |
| 52-Week Range | USD 8.11 – 17.15 |
| Volume | 628,251 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ENTA)
Nexqual's technical model rates ENTA "SELL" based on 3 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.24 (oversold) |
| vs SMA50 | Below (USD 11.68) |
| MACD | -0.61 (negative) |
Earnings (ENTA)
| Next Earnings Date | 2027-02-08 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $14.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.81 vs est -0.77 ▼ miss |
| 2026-06-30 | USD -0.67 vs est -0.54 ▼ miss |
| 2026-03-31 | USD -0.45 vs est -0.57 ▲ beat |
| 2025-12-31 | USD -0.42 vs est -0.8 ▲ beat |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (ENTA)
| Total Revenue | $63.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -14.90% |
| Gross Margin | +100.00% |
| Operating Margin | -99.01% |
| Profit Margin | -108.33% |
| ROE | -94.19% |
| Debt / Equity | 2.22 |
| Current Ratio | 3.78 |
| Total Cash | $194.51M |
| Total Debt | $177.65M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$36.94M (-56.6% of revenue) |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (ENTA)
Nexqual rates Enanta Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Mixed — Revenue +0.7% (last 4 quarters to Jun 2026 vs the 4 before, SEC), slow |
|---|---|
| Profitability | Weak — Operating margin -90% |
| Balance Sheet | Weak — $195M cash vs $178M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$37M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -63%, ROA -21.3% (last 4 quarters, SEC) |
Ownership (ENTA)
| Insider Ownership | +4.67% |
|---|---|
| Institutional Ownership | +91.49% |
| Shares Outstanding | 29.13M |
| Float | 22.52M |
| Short % of Float | +7.63% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
From Enanta Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-11-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Collaborate or out-license, where and when appropriate, with pharmaceutical partners to accelerate the development and commercialization of our proprietary compounds and/or create combination therapies.
- Our decisions regarding our proprietary programs will be based on the results of our studies and the potential for collaborations, including combinations with one or more drugs targeting other mechanisms of action in these diseases.
- Based on our operating plan, we believe that our existing cash, cash equivalents, and short-term marketable securities as of September 30, 2025, as well as the cash flows from our retained portion of future HCV royalties and the proceeds from our public offering in October 2025, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2029.
- Based on our operating plan, we believe our existing financial resources, as well as the cash flows from our retained portion of future HCV royalties and the proceeds from our October 2025 public offering, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2029.
Partnerships
- Virology: We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.
- Two protease inhibitors developed through our Collaborative Development and License Agreement with AbbVie have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for HCV.
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates
- The regulatory pathway for approval of a therapeutic treatment for COVID-19 such as EDP-235 is continually evolving and may result in unexpected or unforeseen challenges and longer timelines than seen for earlier COVID-19 vaccines and therapeutics.
- Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives in the United States could harm our business.
- Claims that our product candidates or the sale or use of our products infringe the patent or other intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| CGON | CG Oncology, Inc. | USD 79.9 | ▲ 1.22% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt